Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coates, A.
Right arrow Articles by Forbes, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coates, A.
Right arrow Articles by Forbes, J. F.

Journal of Clinical Oncology, Vol 10, 1833-1838, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group

A Coates, V Gebski, D Signorini, P Murray, D McNeil, M Byrne and JF Forbes
Department of Oncology, Royal Prince Alfred Hospital, Camperdown NSW, Australia.

PURPOSE: We observed that quality-of-life (QL) scores, collected to evaluate treatment in a randomized trial in advanced breast cancer, predicted survival duration. This report explores the prognostic associations between QL and survival in more detail. PATIENTS AND METHODS: In a randomized clinical trial comparing intermittent and continuous therapy policies for patients with advanced breast cancer, QL was measured by linear analog self-assessment (LASA) and the Quality- of-Life Index (QLI). Baseline scores and subsequent changes were included in statistical models of survival duration, with and without other prognostic factors. RESULTS: Physician assessment of QLI and patient LASA scores for physical well-being (PWB), mood, nausea and vomiting, appetite, and overall QL (but not pain) at the commencement of treatment were significant predictors of subsequent survival. Scores for PWB and QLI were independent of other prognostic factors. Changes in scores were also prognostically important. Both baseline and change in scores for PWB, mood, pain, and QLI after the first three treatment cycles, but before an arbitrary 180-day time point, were significantly predictive of survival beyond that time. Both QLI and PWB were prognostically independent of tumor response. Although QL improvement was correlated with tumor response, continuous therapy yielded significantly better QL scores, even in nonresponders. CONCLUSION: These findings support the validity of the simple QL measures used in the trial. They are compatible with the simple explanation that patients perceive disease progression before it is clinically evident, but also with a causal relationship between QL and survival duration.


This article has been cited by other articles:


Home page
 JCOHome page
S. Halabi, N. J. Vogelzang, A. B. Kornblith, S.-S. Ou, P. W. Kantoff, N. A. Dawson, and E. J. Small
Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer
J. Clin. Oncol., May 20, 2008; 26(15): 2544 - 2549.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Efficace, P. F. Innominato, G. Bjarnason, C. Coens, Y. Humblet, S. Tumolo, D. Genet, M. Tampellini, A. Bottomley, C. Garufi, et al.
Validation of Patient's Self-Reported Social Functioning As an Independent Prognostic Factor for Survival in Metastatic Colorectal Cancer Patients: Results of an International Study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer
J. Clin. Oncol., April 20, 2008; 26(12): 2020 - 2026.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. C. Gotay, C. T. Kawamoto, A. Bottomley, and F. Efficace
The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials
J. Clin. Oncol., March 10, 2008; 26(8): 1355 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. McCarter, W. Furlong, A. C. Whitton, D. Feeny, S. DePauw, A. R. Willan, and R. D. Barr
Health Status Measurements at Diagnosis As Predictors of Survival Among Adults With Brain Tumors
J. Clin. Oncol., August 1, 2006; 24(22): 3636 - 3643.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
H. M. Mehanna and R. P. Morton
Does Quality of Life Predict Long-term Survival in Patients With Head and Neck Cancer?
Arch Otolaryngol Head Neck Surg, January 1, 2006; 132(1): 27 - 31.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Maltoni, A. Caraceni, C. Brunelli, B. Broeckaert, N. Christakis, S. Eychmueller, P. Glare, M. Nabal, A. Vigano, P. Larkin, et al.
Prognostic Factors in Advanced Cancer Patients: Evidence-Based Clinical Recommendations--A Study by the Steering Committee of the European Association for Palliative Care
J. Clin. Oncol., September 1, 2005; 23(25): 6240 - 6248.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Wenzel, H. Q. Huang, B. J. Monk, P. G. Rose, and D. Cella
Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study
J. Clin. Oncol., August 20, 2005; 23(24): 5605 - 5612.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Meyerhardt, J. A. Sloan, D. J. Sargent, R. M. Goldberg, M. Pollak, R. F. Morton, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, and C. S. Fuchs
Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer
Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1402 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
F. Toscani, C. Brunelli, G. Miccinesi, M. Costantini, M. Gallucci, M. Tamburini, E. Paci, P. Di Giulio, and C. Peruselli
Predicting survival in terminal cancer patients: clinical observation or quality-of-life evaluation?
Palliative Medicine, April 1, 2005; 19(3): 220 - 227.
[Abstract] [PDF]

Home page
 JCOHome page
F. Efficace and A. Bottomley
Toward a Clearer Understanding of the Prognostic Value of Health-Related Quality-of-Life Parameters in Breast Cancer
J. Clin. Oncol., February 20, 2005; 23(6): 1335 - 1336.
[Full Text] [PDF]

Home page
 JCOHome page
P. J. Goodwin and M. Ennis
In Reply:
J. Clin. Oncol., February 20, 2005; 23(6): 1336 - 1336.
[Full Text] [PDF]

Home page
 JCOHome page
P. J. Goodwin, M. Ennis, L. J. Bordeleau, K. I. Pritchard, M. E. Trudeau, J. Koo, and N. Hood
Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables
J. Clin. Oncol., October 15, 2004; 22(20): 4184 - 4192.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
A. S. Pickard, L.-A. Topfer, and D. H. Feeny
A Structured Review of Studies on Health-Related Quality of Life and Economic Evaluation in Pediatric Acute Lymphoblastic Leukemia
J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 102 - 125.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
M. S. Donaldson
Taking Stock of Health-Related Quality-of-Life Measurement in Oncology Practice in the United States
J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 155 - 167.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. Mouridsen, Y. Sun, M. Gershanovich, R. Perez-Carrion, D. Becquart, H.A. Chaudri-Ross, and R. Lang
Superiority of Letrozole to Tamoxifen in the First-Line Treatment of Advanced Breast Cancer: Evidence from Metastatic Subgroups and a Test of Functional Ability
Oncologist, September 1, 2004; 9(5): 489 - 496.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Efficace, P. Therasse, M. J. Piccart, C. Coens, K. Van Steen, M. Welnicka-Jaskiewicz, T. Cufer, J. Dyczka, M. Lichinitser, L. Shepherd, et al.
Health-Related Quality of Life Parameters As Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study
J. Clin. Oncol., August 15, 2004; 22(16): 3381 - 3388.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, L. Biganzoli, T. Cufer, R. E. Coleman, C. Coens, F. Efficace, H. A. Calvert, T. Gamucci, C. Twelves, P. Fargeot, et al.
Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study
J. Clin. Oncol., July 1, 2004; 22(13): 2576 - 2586.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, D. A. Berry, S. Woolf, D. Duggan, A. Kornblith, L. N. Harris, R. A. Michaelson, J. A. Kirshner, G. F. Fleming, M. C. Perry, et al.
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
J. Clin. Oncol., June 1, 2004; 22(11): 2061 - 2068.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. N. Cormier and M. T. Ballo
Editorial: Functional Outcome after Treatment of Lower Extremity Soft Tissue Sarcoma: What Should We Tell Our Patients?
Ann. Surg. Oncol., May 1, 2004; 11(5): 453 - 454.
[Full Text] [PDF]

Home page
 Stat Methods Med ResHome page
D. L Fairclough
Patient reported outcomes as endpoints in medical research
Statistical Methods in Medical Research, April 1, 2004; 13(2): 115 - 138.
[Abstract] [PDF]

Home page
 JCOHome page
M. J. Fisch, M. L. Titzer, J. L. Kristeller, J. Shen, P. J. Loehrer, S.-H. Jung, S. D. Passik, and L. H. Einhorn
Assessment of Quality of Life in Outpatients With Advanced Cancer: The Accuracy of Clinician Estimations and the Relevance of Spiritual Well-Being--A Hoosier Oncology Group Study
J. Clin. Oncol., July 15, 2003; 21(14): 2754 - 2759.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. T. Eton, D. L. Fairclough, D. Cella, S. E. Yount, P. Bonomi, and D. H. Johnson
Early Change in Patient-Reported Health During Lung Cancer Chemotherapy Predicts Clinical Outcomes Beyond Those Predicted by Baseline Report: Results From Eastern Cooperative Oncology Group Study 5592
J. Clin. Oncol., April 15, 2003; 21(8): 1536 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D.F. Roychowdhury, A. Hayden, and A.M. Liepa
Health-Related Quality-of-Life Parameters as Independent Prognostic Factors in Advanced or Metastatic Bladder Cancer
J. Clin. Oncol., February 15, 2003; 21(4): 673 - 678.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Modi, K. S. Panageas, E. T. Duck, A. Bach, N. Weinstock, J. Dougherty, L. Cramer, C. Hudis, L. Norton, and A. Seidman
Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer
J. Clin. Oncol., September 1, 2002; 20(17): 3665 - 3673.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Osoba, D. J. Slamon, M. Burchmore, and M. Murphy
Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer
J. Clin. Oncol., July 15, 2002; 20(14): 3106 - 3113.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Cardoso, A. Di Leo, C. Lohrisch, C. Bernard, F. Ferreira, and M. J. Piccart
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
Ann. Onc., February 20, 2002; 13(2): 197 - 207.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sloan, C. L. Loprinzi, J. A. Laurine, P. J. Novotny, D. Vargas-Chanes, J. E. Krook, M. J. O'Connell, J. W. Kugler, M. T. Tirona, C. G. Kardinal, et al.
A Simple Stratification Factor Prognostic for Survival in Advanced Cancer: The Good/Bad/Uncertain Index
J. Clin. Oncol., August 1, 2001; 19(15): 3539 - 3546.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J M Blazeby, S T Brookes, and D Alderson
The prognostic value of quality of life scores during treatment for oesophageal cancer
Gut, August 1, 2001; 49(2): 227 - 230.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. S. Coates, C. Hurny, H. F. Peterson, J. Bernhard, M. Castiglione-Gertsch, R. D. Gelber, and A. Goldhirsch
Quality-of-Life Scores Predict Outcome in Metastatic but Not Early Breast Cancer
J. Clin. Oncol., November 15, 2000; 18(22): 3768 - 3774.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Norris, K. I. Pritchard, K. James, J. Myles, K. Bennett, S. Marlin, J. Skillings, B. Findlay, T. Vandenberg, P. Goss, et al.
Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
J. Clin. Oncol., June 12, 2000; 18(12): 2385 - 2394.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. Vigano, E. Bruera, G. S. Jhangri, S. C. Newman, A. L. Fields, and M. E. Suarez-Almazor
Clinical Survival Predictors in Patients With Advanced Cancer
Arch Intern Med, March 27, 2000; 160(6): 861 - 868.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
H. Faller, H. Bulzebruck, P. Drings, and H. Lang
Coping, Distress, and Survival Among Patients With Lung Cancer
Arch Gen Psychiatry, August 1, 1999; 56(8): 756 - 762.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bernhard, B. Thurlimann, S.-F. H. Schmitz, M. Castiglione-Gertsch, F. Cavalli, R. Morant, M.F. Fey, H. Bonnefoi, A. Goldhirsch, and C. Hurny
Defining Clinical Benefit in Postmenopausal Patients With Breast Cancer Under Second-Line Endocrine Treatment: Does Quality of Life Matter?
J. Clin. Oncol., June 1, 1999; 17(6): 1672 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 Eval Health ProfHome page
A. J. Martin and M. Stockler
Quality-of-Life Assessment in Health Care Research and Practice
Eval Health Prof, June 1, 1998; 21(2): 141 - 156.
[Abstract] [PDF]

Home page
 Eval Health ProfHome page
C. C. Gotay and M. Wilson
Use of Quality-of-Life Outcome Assessments in Current Cancer Clinical Trials
Eval Health Prof, June 1, 1998; 21(2): 157 - 178.
[Abstract] [PDF]

Home page
 Palliat MedHome page
M. Richards and A. Ramirez
Quality of life: the main outcome measure of palliative care
Palliative Medicine, March 1, 1997; 11(2): 89 - 92.
[PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1992 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online